Key Trends in Transcatheter Tricuspid Valve Interventions
Key Trends in Transcatheter Tricuspid Valve Interventions
Highlighted on March 24, 2025 during CRT 2025 sessions. Steven Bolling, professor of cardiac surgery at the University of Michigan, spoke on this topic in sessions at (CRT) 2025 meeting. He provided an overview of the tricuspid space, discussing key trends and future directions in the field.
Original event: Cardiovascular Research Technologies (CRT) 2025
Background : Despite the prevalence and seriousness of this condition, there have historically been limited effective options for medical or surgical management, and only limited transcatheter treatment options are currently available. Transcatheter edge-to-edge repair (t-TEER) for the tricuspid valve using the TriClip device is a relatively new FDA approved technology for treating symptomatic patients suffering from severe or greater tricuspid regurgitation. CMS proposes that TEER will be covered for patients with symptomatic TR despite optimal medical therapy. Early Experience With Transcatheter Tricuspid Valve Replacement Using The Evoque ™ Valve For The Treatment Of Severe Tricuspid Regurgitation was also highlighted in CRT2025 meeting.
1. Tricuspid valve disease has historically been underdiagnosed and undertreated, but recent advances in transcatheter interventions are set to change that. Transcatheter therapies are changing the landscape.
2. For years, he said the valve was largely ignored because it was assumed that treating the mitral valve would indirectly improve tricuspid regurgitation. However, data over the years have proven that approach ineffective, and treatment strategies have evolved significantly. Today, even in isolated tricuspid valve cases, surgical outcomes have improved, with mortality rates now around 4–5%, yet many patients remain high-risk and underserved.
3. Transcatheter tricuspid annuloplasty rings are a major unmet need; Surgeons see strong potential for transcatheter annuloplasty rings, similar to those used in surgery, to improve outcomes with less invasiveness.
4. New devices like the Amend system are in development, though current challenges include limited imaging clarity and device complexity during procedures.
5. Tricuspid interventions have shown improvements in patient-reported quality of life.
6. Approved devices like Abbott’s TriClip and Edwards’ Evoque were adapted from mitral valve technologies, but second-generation, tricuspid-specific devices are emerging.
7. Structural heart teams are seeing a rise in referrals for tricuspid disease, echoing the early years of TAVR expansion and signaling growing recognition of its clinical importance.
Steven F. Bolling, MD https://cdmcd.co/gamWMZ #CRT2025